FindTrial
Sign In

Monitoring immune microenvironment and disease progression of lung cancer brain metastases

Monitoring immune microenvironment and disease progression of lung cancer brain metastases based on multiomics technology

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400082182
Enrollment
Unknown
Registered
2024-03-22
Start date
2024-05-01
Completion date
Unknown
Last updated
2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer brain metastases

Interventions

Case series:NA

Sponsors

The First Affiliated Hospital of University of Science and Technology of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) Aged=18,and =75 years old 2) Dignosed as NSCLC BM according to imaging and histopathological examination,; 3) Available compliant organization and CSF samples; 4) Agree to provide clinical information such as demography, medical history, imaging diagnosis, pathological diagnosis, classification and staging.

Exclusion criteria

Exclusion criteria: 1) Not sighed informed consent form; 2) The expected life less than 12 weeks; 3) Blood samples collected from patients who have received allogeneic blood transfusions.

Design outcomes

Primary

MeasureTime frame
recurrence;genome sequencing;—

Countries

China

Contacts

Public ContactChuandong Cheng

The First Affiliated Hospital of University of Science and Technology of China

doctorcd@126.com+86 138 6591 3323

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026